R&D Trends

OncoDNA signs agreement with SOLTI to provide tumor molecular profile analysis to breast cancer patients

Thursday, October 27, 2016

AGATA aims to link patients to clinical studies with targeted drugs based on their Individual tumors

Belgium-based OncoDNA SA, The Cancer Theranostic Company, which supplies the only comprehensive solution from cancer profiling (OncoDEEP&TRACE), combining solid and liquid biopsies analysis to help oncologists with drug treatment options and efficacy monitoring, has signed a partnership agreement, through its Spanish distributor BioSequence, with SOLTI, a non-profit organization dedicated to clinical research in breast cancer with a broad network of leading hospital centers in Spain, Portugal, France and Italy to supply tumor molecular profiling analysis for SOLTI’s AGATA breast cancer screening program.

[Read More]

Certara’s Simcyp division awarded FDA modeling and simulation grant

Thursday, October 20, 2016

Certara, a provider of decision support technology and consulting services for optimizing drug development and improving health outcomes, has announced that the Office of Generic Drugs (OGD), FDA has awarded it a multi-year research grant to create and validate a physiologically-based pharmacokinetic (PBPK) modeling and simulation framework that complements existing models within the Simcyp Population-based Simulator. The new models will predict and simulate the behavior of supersaturating orally-dosed drug products in the human gastro-intestinal (GI) tract. This platform will also permit new product performance to be assessed and compared to reference products.

[Read More]

Cohen Veterans Bioscience, Stanford University partner on PTSD

Wednesday, October 19, 2016

Despite many years of pioneering work characterizing the brains, behavior, and physiology of individuals with post-traumatic stress disorder (PTSD), the field of psychiatry lacks objective biological measures for understanding the many biological variations in people with the same clinical diagnosis of PTSD. This means that there are no reliable ways to determine who will benefit from which treatment. A new collaboration between Cohen Veterans Bioscience and Stanford University School of Medicine seeks to change this by studying clinical biomarkers as a way to help match patients to the best available treatment.

[Read More]

NIH funds additional medical centers for precision medicine research program

Monday, October 17, 2016

The NIH has announced awards to add four regional medical center groups to the national network of healthcare provider organizations (HPOs) that will implement the Precision Medicine Initiative (PMI) Cohort Program. Combined, the new HPOs will receive initial funds of $5.5 million to begin recruitment and build infrastructure. As efforts advance, the centers may receive first-year funds up to a total of $16 million. The four HPOs join awardees announced earlier this year, to enroll interested individuals, gather participants’ health information and biospecimens and provide input on developing plans for the program.

[Read More]

Quanterix, ImmunArray partner on neurodegenerative disease

Friday, October 14, 2016

Quanterix, a company digitizing biomarker analysis to accurately measure change for precision health, has announced it is making a strategic investment in ImmunArray, a molecular diagnostics company advancing the development of novel, multi-marker tests for complex diseases with compelling levels of accuracy. As part of the deal, ImmunArray gains access to Quanterix Simoa technology. Both companies are pioneering new approaches to medical diagnoses in complementary areas of neurological disease, focusing on the identification and analysis of molecular biomarkers in the blood.

[Read More]

NIH Common Fund announces 2016 high-risk, high-reward research awards

Tuesday, October 11, 2016

The High-Risk, High-Reward Research (HRHR) program, supported by the NIH’s Common Fund, awarded 88 grants to highly creative and exceptional scientists with bold approaches to major challenges in biomedical research. The awards span the broad mission of the NIH and include groundbreaking research: engineering immune cells to produce drugs at sites of diseased tissue, developing a sensor to rapidly detect antibiotic resistant bacteria, understanding how certain parasites evade host detection by continually changing their surface proteins and developing implants that run off the electricity generated from the motion of a beating heart.

[Read More]